Home
News
Create
Screeners
Insights
Venmax Drugs & Pharmaceuticals
25.
80
-0.30
(-1.15%)
Market Cap
₹20.66 Cr
PE Ratio
60.70
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.15%
1M
-10.14%
6M
-1.94%
1Y
+5.65%
5Y
+292.10%
View Company Insights
Latest news about Venmax Drugs & Pharmaceuticals
Venmax Drugs Allots 7.75 Lakh Equity Shares Through Warrant Conversion Worth ₹1.16 Crores
4 hours ago
Today
Venmax Drugs and Pharmaceuticals Limited allotted 7,75,000 equity shares on January 21, 2026, through warrant conversion by three non-promoter investors. The conversion was executed at ₹20 per share, generating ₹1,16,25,000 in proceeds and increasing the company's paid-up capital to ₹8,78,29,300. With 64,81,000 warrants still outstanding from the original March 2025 issuance, the company maintains potential for further capital expansion through future conversions.
Venmax Drugs & Pharmaceuticals: Independent Director Dakshita Jain Steps Down
Nov 24, 2025
Venmax Drugs Reports Strong Revenue Growth and Advances Amalgamation with Hatri Pharma
Nov 12, 2025
Venmax Drugs & Pharmaceuticals Reports Rs 3.74 Lakh Profit in Q1 Results
Jul 23, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation